


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 15, 2007,

By: 
Denise M. Vaillancourt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of CALIGIURI et al.

Serial No.: 09/855,342

Examiner: S. Rawlings

Confirmation No.: 8842

Art Unit: 1643

Filed: May 14, 2001

For: METHODS OF THERAPY FOR CANCERS CHARACTERIZED BY
OVEREXPRESSION OF THE HER2 RECEPTOR PROTEIN

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)**

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,
Applicant(s) hereby submits the following information in conformance with 37 C.F.R.
§§1.97 and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed.
- ☐ No copy of the publication _____ listed on the attached Form PTO/SB/08A are being provided because the Office waives the requirement under 37 C.F.R. 1.98 (a) (2) (i) for submitting a copy of each cited U.S. patent and each U. S. patent application publication for all U.S. national patent applications filed after June 30, 2003.
- ☐ No copies of the publications listed on the attached Form PTO/SB/08A are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No. ____ to which the above-identified application claims priority under 35 U.S.C. §120.

- ☐ Publication(s) _____ listed on the attached Form PTO/SB/08A were cited in a foreign search or examination report corresponding to _____ application serial no. _____ and mailed on _____.
- ☐ Enclosed is a copy of a non-English publication(s) _____. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- ☐ Enclosed is a copy of a non-English publication(s) _____. English language publication ____ (copy enclosed) claims priority from this non-English publication.
- ☐ Enclosed is an explanation of non-English publication(s) _____ for which an English translation is not available.
- ☐ Enclosed is an English translation of non-English publication(s) _____ cited in the attached Form PTO/SB/08A.
- ☐ Enclosed is a copy of pending patent Application Serial No. _____.

This Information Disclosure Statement is filed within any one of the following time periods:

- ☐ within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;
- ☐ before the mailing date of a first office action on the merits; or
- ☒ before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Dated: February 15, 2007

Respectfully submitted,

Novartis Vaccines and Diagnostics, Inc.
Intellectual Property – R440
P.O. Box 8097
Emeryville, CA 94662-8097

By:

Jenny Buchbinder
Jenny Buchbinder
Reg. No. 48,588

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/855,342
				Filing Date	May 14, 2001
				First Named Inventor	CALIGIURI et al.
				Group Art Unit	1643
Examiner Name	S. Rawlings				
Sheet	1	of	2	Attorney Docket Number	PL015993.0002 (2300-15993)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.
² See attached Kinds of U.S. Patent Documents.
³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).
⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.
⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/855,342
				Filing Date	May 14, 2001
				First Named Inventor	CALIGIURI et al.
				Group Art Unit	1643
				Examiner Name	S. Rawlings
Sheet	2	of	2	Attorney Docket Number	PL015993.0002 (2300-15993)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹	
	AA	BURGESS et al., "POSSIBLE DISSOCIATION OF THE HEPARIN-BINDING AND MITOGENIC ACTIVITIES OF HEPARIN-BINDING (ACIDIC FIBROBLAST) GROWTH FACTOR-1 FROM ITS RECEPTOR-BINDING ACTIVITIES BY SITE-DIRECTED MUTAGENESIS OF A SINGLE LYSINE RESIDUE," The Journal of Cell Biology, 111:2129-2138 (1990)		
	AB	LAZAR et al., "TRANSFORMING GROWTH FACTOR α: MUTATION OF ASPARTIC ACID 47 AND LEUCINE 48 RESULTS IN DIFFERENT BIOLOGICAL ACTIVITIES", Molecular and Cellular Biology, 8(3):1247-1252 (1988)		
	AC	LEYLAND-JONES, "DOSE SCHEDULING-HERCEPTIN," Oncology, 61(2):31-36 (2001)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.